At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Single/Multiple Dose Exploratory Clinical Study to Evaluate the Safety, Efficacy, and Cytokinetics of Autologous Humanized Anti-claudin18.2 Chimeric Antigen Receptor T Cell in Advanced Solid Tumor Subjects
In Brief
A Phase 1 clinical trial evaluating CAR-CLDN18.2 T-Cells, PD-1 Monoclonal Antibody, and 1 other intervention for Advanced Solid Tumor. Completed, enrolled 134 participants across 3 sites.
Detailed Summary
An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.
Study Details
Timeline
Interventions
Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses • Chimeric Antigen Receptor T Cells Targeting Claudin18.2
Chimeric Antigen Receptor T Cells Targeting Claudin18.2 with PD-1
First-line systemic therapy according to physician's choice